

# Emmanuel Teiger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1204326/publications.pdf>

Version: 2024-02-01

38  
papers

1,700  
citations

471509

17  
h-index

315739

38  
g-index

38  
all docs

38  
docs citations

38  
times ranked

2445  
citing authors

#	ARTICLE	IF	CITATIONS
1	Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial. <i>Circulation</i> , 2022, 145, 724-738.	1.6	61
2	Prescription, Compliance, and Burden Associated with Salt-Restricted Diets in Heart Failure Patients: Results from the French National OFICSel Observatory. <i>Nutrients</i> , 2022, 14, 308.	4.1	4
3	Prevalence and determinants of iron deficiency in cardiac amyloidosis. <i>ESC Heart Failure</i> , 2022, 9, 1314-1327.	3.1	4
4	Natural history and impact of treatment with tafamidis on major cardiovascular outcome—free survival time in a cohort of patients with transthyretin amyloidosis. <i>European Journal of Heart Failure</i> , 2021, 23, 264-274.	7.1	30
5	Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild-type cardiac amyloidosis. <i>ESC Heart Failure</i> , 2021, 8, 1656-1665.	3.1	11
6	Severe Heart Failure Associated With Tachycardia-Induced Cardiomyopathy Due to Incessant Atrioventricular Re-Entrant Tachycardia. <i>JACC: Case Reports</i> , 2021, 3, 479-483.	0.6	1
7	Design and Rationale of the Swiss-Apero Randomized Clinical Trial: Comparison of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 930-940.	2.4	7
8	Left atrial appendage closure for stroke prevention in atrial fibrillation: Final report from the French left atrial appendage closure registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 788-799.	1.7	2
9	Patent foramen ovale closure in stroke patients with migraine in the CLOSE-MIG study. <i>European Journal of Neurology</i> , 2021, 28, 2700-2707.	3.3	8
10	Frailty in Wild-Type Transthyretin Cardiac Amyloidosis: The Tip of the Iceberg. <i>Journal of Clinical Medicine</i> , 2021, 10, 3415.	2.4	8
11	High Post-Procedural Transvalvular Gradient or Delayed Mean Gradient Increase after Transcatheter Aortic Valve Implantation: Incidence, Prognosis and Associated Variables. The FRANCE-2 Registry. <i>Journal of Clinical Medicine</i> , 2021, 10, 3221.	2.4	7
12	Diagnostic Value of Extracellular Volume Quantification and Myocardial Perfusion Analysis at CT in Cardiac Amyloidosis. <i>Radiology</i> , 2021, 300, 326-335.	7.3	11
13	TAVR Patients Requiring Anticoagulation. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1704-1713.	2.9	31
14	The use of cardiac computed tomography angiography in the assessment of percutaneous left atrial appendage closure—Review and experts recommendations endorsed by the Soci�t� fran�saise d'imagerie cardiaque et vasculaire diagnostique et interventionnelle. <i>Diagnostic and Interventional Imaging</i> , 2021, 102, 586-592.	3.2	3
15	Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment. <i>Journal of Clinical Medicine</i> , 2021, 10, 4868.	2.4	9
16	Echocardiographic Patterns of Left Ventricular Diastolic Function in Cardiac Amyloidosis: An Updated Evaluation. <i>Journal of Clinical Medicine</i> , 2021, 10, 4888.	2.4	4
17	History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis. <i>ESC Heart Failure</i> , 2021, 8, 5501-5512.	3.1	11
18	Diagnostic Performance of Transesophageal Echocardiography and Cardiac Computed Tomography in Infective Endocarditis. <i>Journal of the American Society of Echocardiography</i> , 2020, 33, 1442-1453.	2.8	26

#	ARTICLE	IF	CITATIONS
19	Timing of aortic valve replacement in high-gradient severe aortic stenosis: impact of left ventricular ejection fraction. <i>Acta Cardiologica</i> , 2020, 76, 1-8.	0.9	3
20	Feasibility of Prone Position Coronary Angiography in a Patient With COVID-19 Pneumonia and Refractory Hypoxemia. <i>JACC: Case Reports</i> , 2020, 2, 1302-1306.	0.6	1
21	Left atrial appendage occlusion with the Amplatzerâ„¢ Amuletâ„¢ device: full results of the prospective global observational study. <i>European Heart Journal</i> , 2020, 41, 2894-2901.	2.2	102
22	Carotid versus femoral access for transcatheter aortic valve implantation: a propensity score inverse probability weighting study. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 1140-1146.	1.4	21
23	Angiography and Percutaneous Coronary Intervention for Chronic Total Coronary Occlusion in Daily Practice (from a Large French Registry [CARDIO-ARSIF]). <i>American Journal of Cardiology</i> , 2019, 124, 688-695.	1.6	9
24	Outcomes and safety of same-day discharge after percutaneous coronary intervention: A 10-year single-center study. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 105-111.	1.7	13
25	Aortic Stenosis and Cardiac Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2638-2651.	2.8	182
26	Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry. <i>EuroIntervention</i> , 2018, 14, e590-e597.	3.2	127
27	Baseline characteristics and outcomes after transcatheter aortic-valve implantation in patients with or without previous balloon aortic valvuloplasty: Insights from the FRANCE 2 registry. <i>Archives of Cardiovascular Diseases</i> , 2017, 110, 534-542.	1.6	4
28	Time-Course Reduction in Patient Exposure to Radiation From Coronary Interventional Procedures. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	10
29	Temporal Trends in Transcatheter Aortic Valve Replacement in France. <i>Journal of the American College of Cardiology</i> , 2017, 70, 42-55.	2.8	277
30	Myocardial Gene Expression Profiling to Predict and Identify Cardiac Allograft Acute Cellular Rejection: The GET-Study. <i>PLoS ONE</i> , 2016, 11, e0167213.	2.5	14
31	Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis. <i>International Journal of Cardiology</i> , 2016, 222, 562-568.	1.7	77
32	Transcarotid Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 472-480.	2.9	124
33	Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg?. <i>European Heart Journal</i> , 2016, 37, 3525-3531.	2.2	108
34	Outcomes of primary percutaneous coronary interventions in nonagenarians with acute myocardial infarction. <i>International Journal of Cardiology</i> , 2015, 192, 24-29.	1.7	34
35	Baseline Characteristics and Prognostic Implications of Pre-Existing and New-Onset Atrial Fibrillation After Transcatheter Aortic Valve Implantation. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1346-1355.	2.9	103
36	Effect of Body Mass Index <math>\leq 20 \text{ kg/m}^2</math> on Events in Patients Who Underwent Transcatheter Aortic Valve Replacement. <i>American Journal of Cardiology</i> , 2015, 115, 227-233.	1.6	26

#	ARTICLE	IF	CITATIONS
37	Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score. <i>Heart</i> , 2014, 100, 1016-1023.	2.9	188
38	Ambulatory transradial percutaneous coronary intervention: A safe, effective, and cost-saving strategy. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 15-23.	1.7	39